Advertisement

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

May

12

Today In Oncology

First Virtual Cancer Clinic to Receive ASCO Certified Status

Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival

B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants

Advertisement

© 2026 HSP News Service, L.L.C.